ImmunoGen

ImmunoGen was a United States biotechnology company founded in 1981 and headquartered in Waltham, Massachusetts. The company specialized in antibody-drug conjugates (ADCs), a class of medicines designed to combine the targeting ability of a monoclonal antibody with the cancer-killing activity of a potent chemical payload. In a typical ImmunoGen ADC, the antibody recognizes a molecule expressed on or near a cancer cell, while a chemical linker connects the antibody to a cytotoxic agent. After the conjugate binds to its target and is internalized, the payload is released or activated, allowing treatment to be concentrated more selectively than with an untargeted cytotoxic drug. ImmunoGen's technology portfolio included maytansinoid payloads such as DM1 and DM4, linker systems used to attach those payloads to antibodies, and later DNA-acting IGN payloads. The company's technology was used both in its own development programs and through partnerships and licenses with major pharmaceutical companies. Its most commercially significant technology contribution was associated with ado-trastuzumab emtansine, marketed as Kadcyla by Genentech and Roche. Kadcyla uses a DM1 payload and an ImmunoGen-developed linker approach, and became an important targeted treatment for HER2-positive breast cancer. The company also developed its own antibody-drug conjugate mirvetuximab soravtansine, an FRα-directed product using the DM4 payload and a specialized linker. The medicine was later marketed as Elahere for certain patients with folate receptor alpha-positive ovarian cancer. Other ImmunoGen programs targeted antigens including CD37, EGFR, CD33 and CD123, although several candidates remained investigational or were pursued with partners. ImmunoGen also developed isatuximab, a monoclonal antibody without a toxin-linker conjugate; that program was partnered and subsequently became associated with Sanofi's Sarclisa product. ImmunoGen's business model combined internal oncology research with selective out-licensing and collaboration. Its technology relationships included companies such as Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi and Takeda. These arrangements allowed partner companies to apply ImmunoGen's payload and linker technology to separately selected antibodies and disease targets, while giving ImmunoGen access to development capabilities and potential royalties or milestone economics. In November 2023, AbbVie announced an agreement to acquire ImmunoGen for approximately $10.1 billion. The transaction was intended to give AbbVie control of Elahere and strengthen its oncology portfolio. Following completion of the acquisition, ImmunoGen ceased to operate as an independent publicly traded company. Its history is therefore best understood as that of an ADC technology specialist whose platform influenced multiple partnered medicines and whose internally developed ovarian-cancer therapy became its principal commercial asset.

ImmunoGen was established in 1981 as a biotechnology company pursuing targeted approaches to cancer treatment. Its central scientific idea was to use antibodies as delivery vehicles for highly potent cytotoxic compounds. Conventional chemotherapy can affect healthy and malignant cells alike, whereas an ADC is designed to recognize a molecular marker associated with a tumor, carry a chemical payload to that target and release the payload after the conjugate enters the cell. Over time, ImmunoGen built expertise in three connected parts of ADC design: antibody selection, linker chemistry and payload development. Its best-known payload families included the maytansinoids DM1 and DM4. The company also developed thioether and disulfide-containing linker systems, including technologies associated with the emtansine, mertansine, ravtansine and soravtansine naming conventions. Later programs used DNA-acting IGN payloads intended to expand the range of mechanisms available to ADC developers. A major part of ImmunoGen's history involved collaboration rather than solely independent commercialization. The company licensed or partnered its technology with a number of pharmaceutical companies, including Genentech/Roche, Sanofi, Eli Lilly, Novartis, Bayer HealthCare, Amgen, Biotest and Takeda. One of the most important outcomes was trastuzumab emtansine, an HER2-directed ADC developed and marketed as Kadcyla by Genentech and Roche. The medicine combined trastuzumab with the DM1 payload using an ImmunoGen-associated linker and payload platform. Kadcyla's success demonstrated the commercial potential of ADCs and made ImmunoGen's enabling technology strategically significant beyond its own product pipeline. ImmunoGen also pursued internal drug development. Its principal internally developed program became mirvetuximab soravtansine, also known as IMGN853. The ADC targets folate receptor alpha, a protein expressed in a number of ovarian-cancer tumors, and uses the DM4 payload. The program was evaluated in ovarian cancer, including patients whose disease had progressed after prior treatments. After further clinical development and regulatory review, the product was marketed as Elahere for an indicated ovarian-cancer population. The company's broader pipeline included candidates directed at CD37, EGFR, CD33 and CD123, as well as partnered programs with Sanofi, Eli Lilly, Novartis and other companies. Some of these candidates were discontinued, transferred or remained investigational; the available reference material does not establish a complete final disposition for every program. ImmunoGen also developed isatuximab, a non-conjugated monoclonal antibody that was partnered with Sanofi and later associated with the Sarclisa brand. In November 2023, AbbVie announced that it would acquire ImmunoGen for approximately $10.1 billion. The strategic rationale centered on acquiring Elahere and adding an established ADC platform to AbbVie's oncology activities. The acquisition ended ImmunoGen's life as an independent public company and transferred its assets and programs into AbbVie's pharmaceutical organization. The company is consequently remembered both for its own ovarian-cancer medicine and for foundational technology used in partnered ADC products.

• 2024

  ImmunoGen becomes part of AbbVie

  [3]AbbVie Completes Acquisition of ImmunoGennews.abbvie.com

  The acquisition is completed, ending ImmunoGen's status as an independent publicly traded company.

• 2023

  AbbVie agrees to acquire ImmunoGen

  [2]AbbVie to Acquire ImmunoGennews.abbvie.com

  AbbVie announces a proposed acquisition of ImmunoGen valued at approximately $10.1 billion.

• 2015

  GATSBY trial does not meet its primary endpoint

  [1]ImmunoGenen.wikipedia.org

  A Phase II/III study of trastuzumab emtansine in advanced gastric cancer fails to demonstrate the prespecified primary endpoint.

• 2013

  Kadcyla receives United States approval

  [4]Trastuzumab emtansineen.wikipedia.org

  Trastuzumab emtansine, marketed as Kadcyla, becomes an approved HER2-directed ADC using ImmunoGen-associated technology.

• 1981

  ImmunoGen is founded

  [1]ImmunoGenen.wikipedia.org

  ImmunoGen is established as a biotechnology company focused on targeted cancer therapeutics.

A specialist oncology biotechnology company focused on antibody-drug conjugates, targeted cytotoxic payloads, linker chemistry and licensing partnerships.

• Antibody-drug conjugate

  Mirvetuximab soravtansine

  Mirvetuximab soravtansine, also known as IMGN853, is an antibody-drug conjugate directed at folate receptor alpha. It uses a monoclonal antibody to recognize the target and a DM4 maytansinoid payload connected through an ImmunoGen linker system. The program was developed for ovarian cancer and became the basis of Elahere, a commercial product for an eligible folate receptor alpha-positive ovarian-cancer population.

• Partnered antibody-drug conjugate technology · 2013

  Trastuzumab emtansine

  Trastuzumab emtansine, marketed as Kadcyla by Genentech and Roche, combines the HER2-targeting antibody trastuzumab with the DM1 payload. ImmunoGen supplied important payload and linker technology used in the ADC. The product became one of the best-known clinical and commercial examples of the ADC platform.

• Investigational antibody-drug conjugate

  IMGN779

  IMGN779 was an investigational CD33-directed ADC intended to address acute myeloid leukemia. It used a DNA-alkylating IGN payload rather than the company's earlier maytansinoid approach, illustrating ImmunoGen's effort to broaden ADC mechanisms and target hematologic cancers.

• Investigational antibody-drug conjugate

  IMGN632

  IMGN632 was an investigational ADC directed at CD123, a target associated with several hematologic malignancies. It represented part of ImmunoGen's development work using newer DNA-acting payload technology.

• Monoclonal antibody

  Isatuximab

  Isatuximab is a monoclonal antibody developed by ImmunoGen without an attached cytotoxic payload. The program was partnered with Sanofi and became associated with Sarclisa, a treatment used in multiple myeloma.

• 2023

  Accept AbbVie's acquisition proposalM&A

  Background

  ImmunoGen had developed a commercial oncology asset in mirvetuximab soravtansine and maintained an ADC technology portfolio with partnered applications. AbbVie sought to expand its oncology business and acquire the product and platform.

  Action taken

  AbbVie announced an agreement to acquire ImmunoGen for approximately $10.1 billion.

  Aftermath

  The acquisition was completed in 2024, and ImmunoGen ceased to be an independent public company.

  Announced transaction value. $10.1 billion (November 2023 announcement)

  Source

• 2023

  AbbVie announces agreement to acquire ImmunoGen[2]AbbVie to Acquire ImmunoGennews.abbvie.com

  M&A

  AbbVie announced a transaction valued at approximately $10.1 billion to acquire ImmunoGen, including its antibody-drug conjugate portfolio and mirvetuximab soravtansine.

• 2015

  Kadcyla fails to meet the primary endpoint in the GATSBY trial[1]ImmunoGenen.wikipedia.org

  Other

  The Phase II/III GATSBY study did not meet its primary endpoint when evaluating trastuzumab emtansine against a taxane in previously treated HER2-positive advanced gastric cancer.

1. 1ImmunoGenen.wikipedia.org
2. 2AbbVie to Acquire ImmunoGennews.abbvie.com
3. 3AbbVie Completes Acquisition of ImmunoGennews.abbvie.com
4. 4Trastuzumab emtansineen.wikipedia.org